MedPath

Prednisolone

Generic Name
Prednisolone
Brand Names
Millipred Dp 6 Day
Drug Type
Small Molecule
Chemical Formula
C21H28O5
CAS Number
50-24-8
Unique Ingredient Identifier
9PHQ9Y1OLM
Background

Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication

Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Ma-Spore ALL 2020 Study

First Posted Date
2024-03-28
Last Posted Date
2024-03-28
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT06336395
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Kuala Lumpur, Malaysia

🇸🇬

KK Women's and Children's Hospital, Singapore, Singapore

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Cancer Metastatic
Interventions
Radiation: Stereotactic Ablative Body Radiotherapy (SABR)
Drug: Androgen Deprivation Therapy (ADT)
Other: 177Lu-PSMA-617
Drug: Androgen Receptor Signalling Inhibitor (ARSI)
Radiation: Local Radiotherapy
First Posted Date
2024-03-20
Last Posted Date
2024-08-09
Lead Sponsor
University College, London
Target Recruit Count
8000
Registration Number
NCT06320067
Locations
🇬🇧

University College London Hospitals NHS Foundation Trust, London, United Kingdom

🇬🇧

The Royal Marsden Hospital, Sutton, United Kingdom

🇬🇧

Royal Devon University Hospital Trust, Exeter, United Kingdom

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2
Recruiting
Conditions
B Acute Lymphoblastic Leukemia
Acute Leukemia of Ambiguous Lineage
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: FDG-Positron Emission Tomography
Procedure: Lumbar Puncture
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
First Posted Date
2024-03-19
Last Posted Date
2025-05-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
153
Registration Number
NCT06317662
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Albany Medical Center, Albany, New York, United States

🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 5 locations

The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain

Not Applicable
Recruiting
Conditions
Symptomatic Irreversible Pulpitis
Interventions
Drug: Trypsin, Bromelain and Rutoside
Other: Placebo
First Posted Date
2024-03-07
Last Posted Date
2025-04-09
Lead Sponsor
Cairo University
Target Recruit Count
120
Registration Number
NCT06298383
Locations
🇪🇬

Faculty of Oral and Dental Medicine, Egyptian Russian University, Badr city, Cairo, Egypt

🇪🇬

Faculty of Dentistry, Cairo University, Cairo, Egypt

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

Phase 1
Terminated
Conditions
Polymyalgia Rheumatica
Interventions
First Posted Date
2024-02-28
Last Posted Date
2025-05-16
Lead Sponsor
Sparrow Pharmaceuticals
Target Recruit Count
1
Registration Number
NCT06281236
Locations
🇩🇪

Klinische Forschung Hannover Mitte GmbH/Pratia, Hannover, Germany

🇩🇪

Emovis Gmbh, Berlin, Germany

🇩🇪

Klinikum der Universität München, München, Germany

and more 2 locations

Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus

Phase 4
Not yet recruiting
Conditions
Oral Lichen Planus
Interventions
First Posted Date
2024-02-15
Last Posted Date
2024-02-15
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Target Recruit Count
64
Registration Number
NCT06260904
Locations
🇮🇳

AIIMS Bhubaneswar, Bhubaneswar, Odisha, India

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

First Posted Date
2024-01-23
Last Posted Date
2024-08-19
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Target Recruit Count
324
Registration Number
NCT06220032
Locations
🇳🇱

NL-Breda-AMPHIA, Breda, Netherlands

🇳🇱

NL-Almelo-ZGTALMELO, Almelo, Netherlands

🇳🇱

NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands

and more 22 locations

A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis

Phase 3
Recruiting
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
First Posted Date
2023-12-18
Last Posted Date
2025-02-28
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
300
Registration Number
NCT06174922
Locations
🇮🇳

Chest Clinic, Dept. of Pulmonary Medicine, Chandigarh, India

Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

Not Applicable
Not yet recruiting
Conditions
Severe Alcoholic Hepatitis
Interventions
Drug: Placebo
Other: Standard Medical therapy
First Posted Date
2023-12-04
Last Posted Date
2023-12-04
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
150
Registration Number
NCT06155760
Locations
🇮🇳

Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

© Copyright 2025. All Rights Reserved by MedPath